Back to funds
View filing
Sanofi
institutionalUpdated 17 days agoManaged by Sanofi • Latest filing Q3 2026
Portfolio value
$629.9M
Q3 2026
Filings
4
Quarterly 13F history
Top-10 concentration
100.0%
Weight of largest holdings
Annualized return
156.9%
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 4 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q4 2025 | $310.4M |
| Q1 2026 | $336M |
| Q2 2026 | $534M |
| Q3 2026 | $629.9M |
Top holdings
16 positions as of Q3 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | $134.2M | 12.20M | 21.30% | Unchanged | |
| 2 | $115.9M | 1.16M | 18.40% | Unchanged | |
| 3 | $74.4M | 6.88M | 11.81% | Unchanged | |
| 4 | ? N/A Korsana Biosciences | $63.8M | 1.99M | 10.13% | — |
| 5 | $44.2M | 1.99M | 7.02% | Trimmed(-0.1%) | |
| 6 | $41.3M | 821.9K | 6.56% | Unchanged | |
| 7 | $30.9M | 2.78M | 4.90% | Unchanged | |
| 8 | ? N/A First Tracks Biotherapeutics Inc. | $29.1M | 821.9K | 4.62% | Unchanged |
| 9 | ? N/A Electra Therapeutics Inc | $27.7M | 2.46M | 4.40% | — |
| 10 | ? N/A Attovia Therapeutics Inc | $18.6M | 1.08M | 2.95% | — |
| 11 | ? N/A Latigo Biotherapeutics Inc | $11.2M | 672.8K | 1.78% | — |
| 12 | $11.1M | 2.71M | 1.76% | Unchanged | |
| 13 | $9.3M | 912.0K | 1.48% | Unchanged | |
| 14 | ? N/A Scribe Therapeutics | $9.2M | 500.0K | 1.46% | — |
| 15 | $7M | 2.20M | 1.11% | — | |
| 16 | $2M | 244.1K | 0.32% | Unchanged |